Turkey
Tuberculosis profile
Population  2012 74 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.39 (0.3–0.48) 0.52 (0.41–0.65)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0.01–0.01)
Prevalence  (includes HIV+TB) 17 (7.9–30) 23 (11–40)
Incidence  (includes HIV+TB) 16 (14–18) 22 (19–25)
Incidence (HIV+TB only) 0.033 (0.028–0.037) 0.04 (0.04–0.05)
Case detection, all forms (%) 87 (77–99)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 4 585 (34) Relapse 604 (52)
Smear-negative 2 425 (18) Treatment after failure 98 (8)
Smear-unknown / not done 1 404 (10) Treatment after default 121 (10)
Extrapulmonary 5 121 (38) Other 333 (29)
Other 0 (0)      
Total new 13 535   Total retreatment 1 156  
           
Other (history unknown) 0        
Total new and relapse 14 139   Total cases notified 14 691  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.5 1.6 0.8
Age < 15 50 344 278
Laboratories 2012
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 10.7
Drug susceptibility testing (per 5 million population) 5.1
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 90   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 89  
Retreatment 68  
TB/HIV 2012 Number (%)
TB patients with known HIV status 8 646 (59)
HIV-positive TB patients 45 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 22 (49)
HIV-positive TB patients on antiretroviral therapy (ART) 35 (78)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 3.2 (2.7–3.7) 22 (19–25)
MDR-TB cases among notified pulmonary
TB cases
270 (230–310) 250 (220–290)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 4 742 (71%) 641 (55%) 5 383
Laboratory-confirmed MDR-TB cases 151 140 291
Patients started on MDR-TB treatment     291
Financing TB control 2013
National TB programme budget (US$ millions) 45
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-25 Data: www.who.int/tb/data